# Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

> **NCT02991599** · PHASE4 · COMPLETED · sponsor: **Shanxi Medical University** · enrollment: 196 (actual)

## Conditions studied

- Hepatitis B Vaccine

## Interventions

- **BIOLOGICAL:** 60 µg dose hepatitis B vaccine
- **BIOLOGICAL:** 20 µg dose hepatitis B vaccine

## Key facts

- **NCT ID:** NCT02991599
- **Lead sponsor:** Shanxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-07
- **Final completion:** 2018-05
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2021-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991599, "Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02991599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*